Oral Health Discrepancy
People with severe mental illness exhibit much poorer oral health compared to the general population.
They are nearly three times more likely to have lost all their teeth.
Higher rates of dental decay and tooth loss are observed in individuals with anxiety and depression.
Topics Covered:
Antipsychotics: Treatment regimes for schizophrenia and psychotic conditions.
Mood Stabilizers: Utilization in bipolar disorder.
Definition and Use:
Primarily utilized to manage schizophrenia and other psychotic disorders.
Clinical Implications of Antipsychotics:
Dopamine pathways are critical to understanding schizophrenia symptoms.
Dopamine pathway linked to schizophrenia symptoms
Overactivity in the mesolimbic pathway is associated with positive symptoms (e.g., hallucinations).
→ normal ppl - dopamine mediates attention, reward
however in overactivity in mesolimbic pathway - dopamine abherrent salience - brain misattributing importance to irrelevent stimuli
see chatgpt for red light example
Dysfunction in the mesocortical pathway relates to negative and cognitive symptoms.
Chronic Nature:
Onset typically occurs in early adulthood (20s) and has a prevalence of 1%.
Symptom Classification:
Positive Symptoms: delusions, hallucinations, distressing — respond well to antipsychotics.
Negative Symptoms: Emotional blunting, social withdrawal, apathy — can be disabling and require long-term support.
Cognitive Impairment: a drop in IQ. difficulties in thinking, memory, attention, and problem-solving that affect daily life
First Generation (Typical):
Includes Chlorpromazine, Trifluoperazine, Fluphenazine, Haloperidol, etc.
Second Generation (Atypical):
Includes Olanzapine, Quetiapine, Risperidone, Aripiprazole, Clozapine.
1st vs 2nd Generation:
Atypicals - fewer extra pyramidal side effects (EPSE) (movement disorder), But may cause metabolic side effects. (weight gain)
typical - blocks dopamine receptors
atypical - blocks dopamine and serotonin receptors
Target Interaction:
Acts as antagonists at dopamine D2 receptors which reduces positive psychotic symptoms but does not affect negative symptoms.
Common Mediated Effects:
EPSE arise in the nigrostriatal tract.
Common EPSE:
Acute Dystonia, Parkinsonism, Akathisia, Tardive Dyskinesia
prolactin elevation in tuberoinfundibular system
Other side effects may arise from actions on
serotonin antagonism - sexual dysfunction
histamine antagonism - sedation
muscarinic receptors ant - dry mouth, constipation
alpha adrenergic - postural hypotension
Predominantly Associated with Atypicals:
Common in medications such as Quetiapine and Olanzapine and clozapine
Include weight gain, dyslipidemia, and risk of Type 2 diabetes
atypical
dopamine antagonist
resistant schizophrenia treatment
2 trials, munimum 6 weeks
side effect - sedation, weight gain, constipation, hypersalivation, nutropenia (not enough neutrophil)
atypical
partial agonist at dopamine D2 receptor - modulates dopamine level
acts as antagonist when increase dopamine in mesolimbic area
agonist in mesocortical area
side effect - weight gain, sedation, akathisia, agitaiton NO EPSE
Indications:
Effective in conditions like schizophrenia, severe depression with psychotic features, delusional disorders, and maintenance therapy in bipolar disorder.
Definition:
Mood stabilizers are medications that prevent recurrence of manic and depressive episodes without exacerbating the other pole of mood.
Prevalence: Affects approximately 2% of the population.
Symptomatic Patterns:
Periods of depression and mania with normal mood (euthymia).
Potential for mixed episodes, combining features of both mania and depression.
Depression Core Symptoms:
Persistent feelings of sadness, fatigue, lack of interest…
Mania/Hypomania Symptoms:
Characterized by elevated mood, overactivity , grandiosity,
Manic Episodes:
Enhanced dopamine and glutamate transmission with reduced GABA levels may promote manic episodes.
Depressive Episodes:
Dysregulation of dopamine may contribute to bipolar depression.
Treatments:
Focus on managing episodes and preventing relapses.
Caution advised against typical antidepressants due to potential risk of inducing manic episodes.
Agents:
Lithium, Sodium valproate, and Lamotrigine.
Mechanism of Action:
Modulates excitatory and inhibitory neurotransmission, influencing broad neurochemical systems to stabilize mood.
Pharmacokinetics:
Complete absorption within 6-8 hours; excreted unchanged in urine; with no protein binding.
Side Effects:
Can lead to renal and thyroid issues, with potential for severe toxicity if not monitored.
Sodium Valproate: Enhances GABA neurotransmission; contraindicated in women of childbearing age.
Lamotrigine: Used primarily for maintenance; requires careful titration to mitigate risks.
Carbamazepine: 3rd line treatment; notable for its effects on Na+ channels and impact on hepatic enzyme systems.